Iloprost infusion does not reduce oxidative stress in systemic sclerosis

Rheumatology International

Volumn 28, Issue 4, 2008, Pages 335-337

  Volpe, Alessandro ^a   Biasi, Domenico ^a   Caramaschi, Paola ^a   Bambara, Lisa Maria ^a   Carletto, Antonio ^a   Degan, Maurizio ^a   Minuz, Pietro ^a  

^a UNIVERSITY OF VERONA   (Italy)

Author keywords

F2 isoprostanes; Iloprost; Ischemia reperfusion phenomena; Oxidative stress; Systemic sclerosis

Indexed keywords

8 ISOPROSTAGLANDIN F2 ALPHA; CALCIUM CHANNEL BLOCKING AGENT; ILOPROST; ISOPROSTANE DERIVATIVE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; ISCHEMIA; LIPID PEROXIDATION; MALE; OXIDATIVE STRESS; PRIORITY JOURNAL; PROSTAGLANDIN URINE LEVEL; REPERFUSION; SYSTEMIC SCLEROSIS;

DINOPROST; FEMALE; HUMANS; ILOPROST; INFUSIONS, PARENTERAL; MALE; MIDDLE AGED; OXIDATIVE STRESS; SCLERODERMA, SYSTEMIC; TIME FACTORS; TREATMENT OUTCOME; UP-REGULATION; VASODILATOR AGENTS;

EID: 38049069217     PISSN: 01728172     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00296-007-0443-1     Document Type: Article

References (18)

1. Murrell DF (1993) A radical proposal for the pathogenesis of scleroderma. J Am Acad Dermatol 28:78-85
2. Sambo P, Baroni SS, Luchetti M, Paroncini P, Dusi S, Orlandini G, Gabrielli A (2001) Oxidative stress in scleroderma: maintenance of scleroderma fibroblast phenotype by the constitutive upregulation of free radical generation through the NADPH oxidase complex pathway. Arthritis Rheum 44:2653-2664
3. McCord JM (1985) Oxygen-derived free radicals in postischemic tissue injury. N Engl J Med 312:159-163
4. Morrow JD (2005) Quantification of isoprostanes as indices of oxidant stress and the risk of atherosclerosis in humans. Arterioscler Thromb Vasc Biol 25:279-286
5. 2-isoprostanes in systemic sclerosis, but not in primary Raynaud's phenomenon. Arthritis Rheum 46:1319-1323
6. 2-isoprostanes in systemic sclerosis: correlation with clinical features. Rheumatology 45:314-320
7. Pope J, Fenlon D, Thompson A, Shea B, Furst D, Wells G, Silman A (2000) Iloprost and cisaprost for Raynaud's phenomenon in progressive systemic sclerosis. Cochrane Database Syst Rev 2:CD000953
8. Ferrari R, Cargnoni A, Curello S, Boffa GM, Ceconi C (1989) Effects of iloprost (ZK 36374) on glutathione status during ischaemia and reperfusion of rabbit isolated hearts. Br J Pharmacol 98:678-684
9. Bozkurt AK (2002) Alpha-tocopherol (vitamin E) and iloprost attenuate reperfusion injury in skeletal muscle ischemia/reperfusion injury. J Cardiovasc Surg (Torino) 43:693-696
10. Aytac E, Oktay Seymen H, Uzun H, Dikmen G, Actuq T (2006) Effects of iloprost on visual evoked potentials and brain tissue oxidative stress after bilateral common carotid artery occlusion. Prostaglandins Leukot Essent Fatty Acids 74:373-378
11. Emrecan B, Tulukoglu E, Bozok S, Kestelli M, Onem G, Kupelioqlu A, Yaqdi S, Gurbuz A (2006) Effects of Iloprost and pentoxifylline on renal ischemia-reperfusion in rabbit model. Eur J Med Res 11:295-299
12. Herrick AL, Rieley F, Schofield D, Hollis S, Braganza JM, Jayson MI (1994) Micronutrient antioxidant status in patients with primary Raynaud's phenomenon and systemic sclerosis. J Rheumatol 21:1477-1488
13. Lundberg AC, Akesson A, Akesson B (1992) Dietary intake and nutritional status in patients with systemic sclerosis. Ann Rheum Dis 51:1143-1148
14. Baroni SS, Santillo M, Bevilacqua F, Luchetti M, Spadoni T, Mancini M, Fraticelli P, Sambo P, Funaro A, Kazlauskas A, Avvedimento EV, Gabrielli A (2006) Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis. N Engl J Med 354:2667-2676
15. Caramaschi P, Canestrini S, Biasi D, Martinelli N, Perbellini L, Carletto A, Pieropan S, Volpe A, Bambara LM (2006) Evaluation of finger skin temperature in scleroderma patients cyclically treated with iloprost. Joint Bone Spine 73:57-61
16. Kahaleh BM, Fan PG, Matucci Cerinic M (2000) Modulation of endothelial gene expression by prostacyclin in systemic sclerosis. Arthritis Rheum 43 (Suppl):1148
17. Della Bella S, Molteni M, Mocellin C, Fumagalli S, Bonara P, Scorza R (2001) Novel mode of action of iloprost: in vitro down-regulation of endothelial cell adhesion molecules. Prostaglandins 65:73-83
18. Della Bella S, Molteni M, Mascagni B, Zulian C, Compasso S, Scorza R (1997) Cytokine production in scleroderma patients: effects of therapy with either iloprost or nifedipine. Clin Exp Rheumatol 15:135-141